When Sequenom releases its second-quarter earnings Thursday morning, investors, customers, and collaborators will be looking to see whether the company can arrest a six-month slide in its stock price.

Though quarterly revenues have grown since the second period last year, receipts for the first three months of 2004 have fallen by $2.3 million year over year because of a challenging market for high-throughput genotyping systems.